首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   10篇
  免费   1篇
基础医学   1篇
临床医学   2篇
外科学   3篇
综合类   1篇
预防医学   1篇
肿瘤学   3篇
  2021年   1篇
  2011年   2篇
  2010年   1篇
  2007年   1篇
  2001年   1篇
  1999年   2篇
  1998年   1篇
  1996年   1篇
  1995年   1篇
排序方式: 共有11条查询结果,搜索用时 31 毫秒
1.
目的 观察消炎痛(Indomethacin)对有转移潜能的人肝癌MHCC97L细胞增殖侵袭的影响和对裸鼠肝癌生长和转移的抑制作用.方法 (1)体外实验:采用0.2 mmol/L的消炎痛分别作用于MHCC97L细胞,观察细胞增殖、侵袭实验、运动实验和血管内皮生长因子(VEGF)和基质金属蛋白酶2(MMP-2)蛋白表达[酶联免疫吸附试验(ELISA)].(2)体内实验:建立转移性人肝癌裸鼠原位模型后,将裸鼠随机分为对照组和消炎痛组.6周后处死动物,测量肿瘤体积,计算抑瘤率、肺转移灶数目及肺转移率.免疫组织化学方法检测VEGF、MMP-2、环氧合酶-2(COX-2)蛋白的表达.结果 (1)体外实验:0.2mmol/L消炎痛明显抑制MHCC97L细胞增殖(P值均<0.01),消炎痛组穿过人工基底膜(侵袭实验)和上室底膜(运动实验)的细胞数分别为2.2±1.3和4.4±1.1,明显低于对照组(11.4±1.9和12.8±1.8,P值均<0.01);ELISA法检测发现,消炎痛组VEGF蛋白和MMP-2蛋白含量和对照组比较明显降低(P值均<0.01).(2)体内实验:对照组、消炎痛组肿瘤体积分别为(1700 ±422)mm3 和(1170±585)mm3(P<0.05),肺转移率分别为75%和50%(P>0.05),平均肺转移灶数目分别为2.92±2.07和1.33±1.56(P<0.05);与对照组比较,消炎痛组的抑瘤率为31.2%.免疫组织化学染色显示,消炎痛组VEGF、MMP-2、COX-2蛋白的表达和对照组比较均有降低(P值均<0.01).结论 在一定条件下,消炎痛可抑制肝细胞肝癌的生长转移,其作用和抑制VEGF蛋白和MMP-2蛋白的表达有关.
Abstract:
Objective To study the effects of indomethacin on proliferation and invasion of hepatocellular carcinoma (HCC) cell line MHCC97L with metastatic potential and the effect of indomethacin on the growth and metastasis of HCC. Methods (1) In vitro; Proliferation, Transwell invasion assay, cell motility assay, vascular endothelial growth factor (VEGF) and matrix metalloproteinase-2 (MMP-2) protein activity were evaluated after cells were treated with 0. 2 mmol/L indomethacin. (2)In vivo: Mice bearing xenografts in the liver were randomly divided into control and indomethacin groups. At the end of sixth week, the mice were killed and tumor volume, inhibitory rate, immunohistochemistry assay (IHA) and metastasis were evaluated. Results (1)In vitro; 0. 2 mmol/L indomethacin could inhibit the proliferation of MHCC97L cells markedly (P <0. 01). The average amount of invading cells per field in cell invasion assay and motility assay was 2. 2 ± 1. 3 and 4.4 ± 1. 1 respectively in indomethacin group, significantly less than in control group ( 11. 4 ± 1. 9 and 12. 8 ± 1. 8 respectively, P <0. 01). The expression of VEGF and MMP-2 in cells treated with indomethacin was significantly lower than in control group (P <0. 01). (2)In vivo; Tumor volume, incidence and number of lung metastases in control and indomethacin groups were (1700 ±422) mm3 and (1170 ± 585) mm3 (P < 0. 05), 75% and 50% ( P > 0.05), 2. 92 ± 2. 07 and 1.33 ±1.56 (P<0. 05) , respectively. Inhibition rate in indomethacin group was 31.2%. IHA showed that the expression of VEGF, MMP-2, and cyclooxygenase-2 ( COX-2) was down-regulated in indomethacin group (P <0.01). Conclusion Indomethacin could inhibit the growth and metastasis of HCC, which was in part mediated by down-regulation of VEGF and MMP-2.  相似文献   
2.
原发性肝癌(PLC)是一种发病率高,死亡率高,手术切除率低,术后易复发转移的恶性肿瘤。液体活检是将人体体液或者血液中的某些微小的成分通过特殊的方法富集,再进行浓缩,扩增和荧光染色等处理后,用专门的设备进行检测,从而了解体液中具有的肿瘤或基因特征的信息,实现了对人体内的肿瘤相关状态从新的角度进行监测的方法。液体活检研究提供了可能早期发现肝癌,评估术后疗效和预后的新途径。液体活检技术主要包括循环肿瘤细胞(CTCs)、循环游离核酸(CFNA)和外泌体(exosomes)检测,它们在检测技术和临床应用方面各有特色,新近的PCR+分子测序技术将有助于此项研究。作者对肝癌液体活检的几种类型和特点进行综述并展望了未来的发展方向。  相似文献   
3.
原发性肝癌的动脉供血特点   总被引:1,自引:0,他引:1  
目的 探讨供血动脉分型与肝癌的生物学特性的关系及其对临床治疗选择的意义。 方法 分析和统计了419例巨块型原发性肝癌(>10cm)患者的动脉造影资料及临床资料。 结果 根据供血动脉数量的多少及形态,把原发性肝癌的供血动脉分为中央型、外周型、混合型和少供血型四种。前三型为多供血型,占7184%,少供血型占2816%。中央型根据血管的分支形态分为穿透型、树枝型、团状型三种亚型,分别占中央型的4063%、5260%、677%。外周型根据供血动脉的数量分为单枝型和多枝型两种亚型,分别占外周型的3043%和6957%。外周型肝癌患者的1年和2年生存率较中央型和混合型高,而少供血型肝癌较多供血型低。 结论 肝癌的供血动脉分型对肿瘤生物学特性的了解、临床治疗的选择及预后的判断具有重要的意义  相似文献   
4.
目的 :探讨联合应用生长激素和谷氨酰胺对短肠大鼠小肠粘膜吸收功能的影响。材料和方法 :研究选用 40只手术成功的SD短肠大鼠 ,按 2× 2析因实验设计随机分为四组 ,分别给予常规全肠外营养、附加谷氨酰胺、附加生长激素及附加谷氨酰胺和生长激素全肠外营养 ,持续 6天。应用生化酶学的方法测定各组小肠粘膜上皮Na+ ,K+ ATPase的活性。结果 :谷氨酰胺组小肠粘膜Na+ ,K+ ATPase的活性较常规组明显增高 ;生长激素组Na+ ,K+ ATPase的活性无明显增高 ;而联合应用谷氨酰胺和生长激素组小肠粘膜上皮Na+ ,K+ ATPase的活性较常规组亦有显著性增高。结论 :研究表明联合应用谷氨酰胺和生长激素能够有效的增加小肠粘膜上皮Na+ ,K+ AT Pase的活性 ,从而提高其吸收功能。  相似文献   
5.
Objective To study the effects of indomethacin on proliferation and invasion of hepatocellular carcinoma (HCC) cell line MHCC97L with metastatic potential and the effect of indomethacin on the growth and metastasis of HCC. Methods (1) In vitro; Proliferation, Transwell invasion assay, cell motility assay, vascular endothelial growth factor (VEGF) and matrix metalloproteinase-2 (MMP-2) protein activity were evaluated after cells were treated with 0. 2 mmol/L indomethacin. (2)In vivo: Mice bearing xenografts in the liver were randomly divided into control and indomethacin groups. At the end of sixth week, the mice were killed and tumor volume, inhibitory rate, immunohistochemistry assay (IHA) and metastasis were evaluated. Results (1)In vitro; 0. 2 mmol/L indomethacin could inhibit the proliferation of MHCC97L cells markedly (P <0. 01). The average amount of invading cells per field in cell invasion assay and motility assay was 2. 2 ± 1. 3 and 4.4 ± 1. 1 respectively in indomethacin group, significantly less than in control group ( 11. 4 ± 1. 9 and 12. 8 ± 1. 8 respectively, P <0. 01). The expression of VEGF and MMP-2 in cells treated with indomethacin was significantly lower than in control group (P <0. 01). (2)In vivo; Tumor volume, incidence and number of lung metastases in control and indomethacin groups were (1700 ±422) mm3 and (1170 ± 585) mm3 (P < 0. 05), 75% and 50% ( P > 0.05), 2. 92 ± 2. 07 and 1.33 ±1.56 (P<0. 05) , respectively. Inhibition rate in indomethacin group was 31.2%. IHA showed that the expression of VEGF, MMP-2, and cyclooxygenase-2 ( COX-2) was down-regulated in indomethacin group (P <0.01). Conclusion Indomethacin could inhibit the growth and metastasis of HCC, which was in part mediated by down-regulation of VEGF and MMP-2.  相似文献   
6.
原发性肝癌的供血动脉解剖分析   总被引:12,自引:1,他引:11  
目的:探讨供血动脉分型与肝癌的生物学特性的关系及其对临床治疗选择的意义。方法:分析和统计了419例巨块型原发性肝癌患者的动脉造影资料及临床资料。结果:根据供血动脉的数量的多少及形态,把原发性肝癌的供血动脉分为中央型,外周型,混合型和少供血型四种。前三型为多供血型,占71.84%,少供血型占28.16%,中央型根据血管的分枝形态分为穿透型,树枝型,团状型三种亚型,分别占中央型的40.63%,52.6  相似文献   
7.
槐耳浸膏的实验研究及临床应用进展   总被引:3,自引:0,他引:3  
槐耳颗粒目前在临床肿瘤治疗中运用较为广泛。全文对槐耳的菌质制备、化学研究、作用机制、药理及毒理研究、临床应用等方面作一综述,旨在为槐耳的进一步研究提供帮助。  相似文献   
8.
CO_2作为超声造影剂在临床肝癌超声诊断中的价值已得到肯定,但多为经肝动脉进行CO_2超声造影(CO_2-EUS)的,而经门静脉进行CO-EUS,到目前为止,未见有公开报道,本文通过肝癌模型进行门静脉CO_2-EUS,以探讨其临床应用的可行性及实用价值。  相似文献   
9.
Objective To study the effects of indomethacin on proliferation and invasion of hepatocellular carcinoma (HCC) cell line MHCC97L with metastatic potential and the effect of indomethacin on the growth and metastasis of HCC. Methods (1) In vitro; Proliferation, Transwell invasion assay, cell motility assay, vascular endothelial growth factor (VEGF) and matrix metalloproteinase-2 (MMP-2) protein activity were evaluated after cells were treated with 0. 2 mmol/L indomethacin. (2)In vivo: Mice bearing xenografts in the liver were randomly divided into control and indomethacin groups. At the end of sixth week, the mice were killed and tumor volume, inhibitory rate, immunohistochemistry assay (IHA) and metastasis were evaluated. Results (1)In vitro; 0. 2 mmol/L indomethacin could inhibit the proliferation of MHCC97L cells markedly (P <0. 01). The average amount of invading cells per field in cell invasion assay and motility assay was 2. 2 ± 1. 3 and 4.4 ± 1. 1 respectively in indomethacin group, significantly less than in control group ( 11. 4 ± 1. 9 and 12. 8 ± 1. 8 respectively, P <0. 01). The expression of VEGF and MMP-2 in cells treated with indomethacin was significantly lower than in control group (P <0. 01). (2)In vivo; Tumor volume, incidence and number of lung metastases in control and indomethacin groups were (1700 ±422) mm3 and (1170 ± 585) mm3 (P < 0. 05), 75% and 50% ( P > 0.05), 2. 92 ± 2. 07 and 1.33 ±1.56 (P<0. 05) , respectively. Inhibition rate in indomethacin group was 31.2%. IHA showed that the expression of VEGF, MMP-2, and cyclooxygenase-2 ( COX-2) was down-regulated in indomethacin group (P <0.01). Conclusion Indomethacin could inhibit the growth and metastasis of HCC, which was in part mediated by down-regulation of VEGF and MMP-2.  相似文献   
10.
肿瘤浸润淋巴细胞的表型及功能研究江青综述林芷英审校上海中山医院肝癌研究所(200032)肿瘤浸润淋巴细胞(tumor-infiltratinglymphocyte,TIL)具有杀伤肿瘤细胞、降低转移潜能的作用,因其与肿瘤细胞密切接触而被认为是宿主对肿...  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号